Pharmacokinetics rind Tissue Distribution of a Recombinant truman Erythropoietin, GC-rhEPO

유전자 재조합 사람형 erythropoietin, GC-rhEPO의 약물동태 및 조직분포

  • 김선돈 (서울대학교 수의과대학 약리학교실) ;
  • 한성규 (서울대학교 수의과대학 약리학교실) ;
  • 이호성 (서울대학교 수의과대학 약리학교실) ;
  • 김성남 (서울대학교 수의과대학 약리학교실) ;
  • 정원휘 (서울대학교 수의과대학 약리학교실) ;
  • 백대현 (서울대학교 수의과대학 약리학교실) ;
  • 조은성 (서울대학교 수의과대학 약리학교실) ;
  • 허재욱 ((주)녹십자 종합연구소) ;
  • 류판동 (서울대학교 수의과대학 약리학교실)
  • Published : 2000.06.01

Abstract

To evaluate the pharmacokinetic properties and tissue distribution of a newly developed recombinant human erythropoietin (GC-rhEPO), we analyzed the plasma and tissue levels of erythropoietin by an ELISA after intravenous (IV) and subcutaneous (SC) adminstration to the male rats at the doses of 20, 100, 500 or 2,500 unit/kg. After single IV bolus injection of GC-rhEPO, the plasma concentration was rapidly increased and decreased with two phases with half-lives of 13.4 min and 2.94 hours. AUC was increased dose- dependently but plasma half-lives remained constant regardless of GC-rhEPO doses. Following SC administration, the plasma concentration increased slowly with half-life of 9.2 hours and reached peak at 8 hours. Mean residence time and bioavailability were 18.2 hours and 44%, respectively. After single IV dose of 100 unit/kg, tissue GC-rhEPO level was higher in bone marrow and spleen, while the depletion rate was slower in liver and bone marrow, indicating the higher affinity of GC-rhEPO to bone marrow. Taken together, the experimental results indicate that GC-rhEPO contained the typical pharmacokinetic properties and the tissue distribution patterns inherent to human erythropoietin.

Keywords